Christie DIA NSCLC Research Data Base
Research type
Research Database
IRAS ID
333917
Contact name
Fabio Gomes
Contact email
Research summary
The Christie DIA NSCLC Research Data Base
REC name
North West - Haydock Research Ethics Committee
REC reference
24/NW/0242
Date of REC Opinion
17 Sep 2024
REC opinion
Favourable Opinion
Data collection arrangements
This NSCLC database focuses on patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have undergone treatment with chemoimmunotherapy (for example Pembrolizumab; Atezolizumab; Pembrolizumab + pemetrexed + carboplatin; Pembrolizumab + carboplatin + paclitaxel) from 2018 until 2028, combining data from The Christie EHR with imaging data, patient reported outcome measures and comorbidity data. This will generate a large dataset (approximately 200 patients per year) including data from across the cancer management pathway, treatment toxicity, co-morbidities and efficacy data to inform treatment response and outcomes following immunotherapy in the advanced setting.
Data for the agreed cohort will be exported as an extract to the NSCLC database via the gateway de-identification server on The Christie computer network.
Research programme
Lung cancer is the leading cause of cancer death in the UK. Only 19% of patients diagnosed with advanced stage disease survive for 1 year. Immunotherapy has transformed the treatment of advanced lung cancer in the last 10 years and offers durable benefit to some patients. However, not all patients respond and there is an unmet need to understand the biomarkers and other factors that influence outcome to enable individualised treatment in this setting. It is well-known that patients with underlying comorbidities and socioeconomic deprivation are under-represented in conventional clinical trials and as such the current evidence about immunotherapy is unlikely to extend to these complex groups that form a significant proportion of the lung cancer population in Greater Manchester. Real-world data, the information collected about patients as part of their normal care in hospitals’ Electronic Health Records (EHRs), offers the opportunity to generate evidence where clinical trial data does not or will not exist. Our vision is to make a high-quality real-world dataset available to the scientific community to investigate how immunotherapy might be personalised for advanced lung cancer patients, in particular by linking comorbidity and patient-report outcomes with the traditional efficacy and toxicity outcomes.
Research database title
The Christie DIA NSCLC Research Data Base
Establishment organisation
The Christie Hospital NHS Trust
Establishment organisation address
Wilmslow Road
Manchester
M20 4BX